Israel's Kahr Medical Attracts Investments From Sanofi, Others
This article was originally published in PharmAsia News
Israel's drug maker Kahr Medical is set to receive $1 million investment from Hadasit Bio Holdings, which in turn is getting $2.1 million from French drug-maker Sanofi-Aventis
You may also be interested in...
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.